The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
The impact of estrogen depletion by aromatase inhibitors on adiponectin serum levels in postmenopausal patients with breast cancer.
Georg Pfeiler
Honoraria - Novartis; Roche
Robert Konigsberg
No relevant relationships to disclose
Peyman Hadji
Honoraria - Amgen; AstraZeneca; GlaxoSmithKline; Lilly; Novartis; Pfizer; Roche
Research Funding - Novartis; Pfizer; Roche
Florian Fitzal
Research Funding - AstraZeneca
Other Remuneration - AstraZeneca
Muy-Kheng Maria Tea
No relevant relationships to disclose
Sonja Vogl
No relevant relationships to disclose
Andreas Berger
No relevant relationships to disclose
Ruth Exner
No relevant relationships to disclose
Michael Seifert
No relevant relationships to disclose
Christian F. Singer
Consultant or Advisory Role - AstraZeneca
Michael Gnant
Consultant or Advisory Role - Amgen; AstraZeneca
Honoraria - AstraZeneca; Novartis; Sanofi
Research Funding - Amgen; Novartis; Pfizer; Roche; Sanofi
Peter Christian Dubsky
Honoraria - AstraZeneca; Novartis; Pfizer
Other Remuneration - AstraZeneca; Novartis